Hikma Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Hikma Pharmaceuticals has a total shareholder equity of $2.2B and total debt of $1.1B, which brings its debt-to-equity ratio to 50.9%. Its total assets and total liabilities are $4.7B and $2.5B respectively. Hikma Pharmaceuticals's EBIT is $619.0M making its interest coverage ratio 9.4. It has cash and short-term investments of $229.0M.
Key information
50.9%
Debt to equity ratio
US$1.13b
Debt
Interest coverage ratio | 9.4x |
Cash | US$229.00m |
Equity | US$2.21b |
Total liabilities | US$2.47b |
Total assets | US$4.68b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HKMP.Y's short term assets ($2.1B) exceed its short term liabilities ($1.3B).
Long Term Liabilities: HKMP.Y's short term assets ($2.1B) exceed its long term liabilities ($1.1B).
Debt to Equity History and Analysis
Debt Level: HKMP.Y's net debt to equity ratio (40.6%) is considered high.
Reducing Debt: HKMP.Y's debt to equity ratio has increased from 36.1% to 50.9% over the past 5 years.
Debt Coverage: HKMP.Y's debt is well covered by operating cash flow (54%).
Interest Coverage: HKMP.Y's interest payments on its debt are well covered by EBIT (9.4x coverage).